Get the Stockscreener App
0.9698
6.74%
0.0612
After Hours:
.97
0.0002
+0.02%
Ocugen Inc stock is traded at $0.9698, with a volume of 4.39M.
It is up +6.74% in the last 24 hours and up +4.89% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$0.9086
Open:
$0.93
24h Volume:
4.39M
Relative Volume:
1.22
Market Cap:
$287.80M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-2.6211
EPS:
-0.37
Net Cash Flow:
$-72.53M
1W Performance:
+5.59%
1M Performance:
+4.89%
6M Performance:
-44.58%
1Y Performance:
+149.56%
1-Day Range:
$0.927
$1.01
1-Week Range:
$0.889
$1.01
52-Week Range:
$0.36
$2.105
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.9698 | 287.80M | 0 | -63.08M | -72.53M | -0.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference - GlobeNewswire
Ocugen CEO to Present Clinical Program Updates at NobleCon20 Conference | OCGN Stock News - StockTitan
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen director Kirsten Castillo buys $22,847 in stock - Investing.com India
Ocugen director Kirsten Castillo buys $22,847 in stock By Investing.com - Investing.com Australia
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen Reports Promising Results from OCU410 ArMaDa Trial for Geographic Atrophy - MSN
Ocugen Secures EMA Orphan Designation for OCU410ST, Advancing Stargardt Disease Treatment - MSN
Ocugen Announces European Medicines Agency Grants Orphan - GlobeNewswire
Ocugen reports positive data for OCU400, OCU410 - MSN
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen announces EMA granted orphan medicinal product designation for OCU410ST - TipRanks
Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 - MSN
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease - The Manila Times
Ocugen's Eye Disease Drug Shows 84% Lesion Reduction, Receives EMA Orphan Status | OCGN Stock News - StockTitan
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy - Ophthalmology Times
Ocugen announces preliminary efficacy, safety data from Phase 1/2 OCU410 trial - TipRanks
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen
Ocugen Announces Compelling Preliminary Data for OCU410—a - GlobeNewswire
Ocugen's Eye Treatment Shows 21% Disease Slowdown in Phase 1 Trial Data | OCGN Stock News - StockTitan
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
OCGN Stock: Can New Leadership Save This Biotech Company? - TipRanks
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Appoints Ramesh Ramachandran as Financial Officer - TipRanks
Dow Jones Transportations Average (DOWT) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
Nasdaq Health Care Index (IXHC) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Ocugen: Q3 Earnings Snapshot - New Haven Register
Ocugen, Inc. (OCGN) Quarterly 10-Q Report - Quartzy
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
SEC Form 10-Q filed by Ocugen Inc. - Quantisnow
HC Wainwright Has Pessimistic View of Ocugen FY2024 Earnings - MarketBeat
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen to Present Innovations at Nasdaq Clinical Showcase - TipRanks
Navigating 4 Analyst Ratings For Ocugen - Benzinga
Ocugen (NASDAQ:OCGN) Given Buy Rating at HC Wainwright - MarketBeat
Chardan Capital Reaffirms Buy Rating for Ocugen (NASDAQ:OCGN) - MarketBeat
Earnings call: Ocugen outlines progress in ophthalmology trials, financials - Investing.com
Earnings call: Ocugen outlines progress in ophthalmology trials, financials By Investing.com - Investing.com Australia
Ocugen, Inc. (NASDAQ:OCGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Ocugen: Progress in Gene Therapy and Financial Outlook - TipRanks
Ocugen (OCGN) Q3 2024 Earnings Call Transcript - The Motley Fool
OCGN Earnings: Ocugen’s Q3 Results Disappoint - TipRanks
Ocugen receives $30M credit facility to fund, allocate resources across company - Pennsylvania Business Report
Ocugen reports Q3 revenue $1.136M, consensus $300,000 - TipRanks
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):